LINVOSELTAMAB

UNII:	M3CPC50MZS
Type:	INGREDIENT SUBSTANCE
Formula:
Preferred Substance Name:	LINVOSELTAMAB
GSRS Full Record:	M3CPC50MZS i

2408319-25-3
Human IgG4-based anti-CD3 x anti-BCMA bispecific monoclonal antibody that binds to CD3 and BCMA
IMMUNOGLOBULIN G4 (103-CYSTEINE,108-CYSTEINE,233-PROLINE,238-PROLINE,239-VALINE,240-ALANINE,DE-241-GLYCINE), ANTI-(HUMAN B-CELL MATURATION ANTIGEN) (HUMAN MONOCLONAL REGN5458 .GAMMA.4-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL REGN5458 .KAPPA.-CHAIN, (231->230'),(234->233')-BIS(DISULFIDE) WITH IMMUNOGLOBULIN G4 (232-PROLINE,237-PROLINE,238-VALINE,239-ALANINE,DE-240-GLYCINE,439-ARGININE,440-PHENYLALANINE,449-PROLINE) ANTI-(HUMAN CD3 ANTIGEN) (HUMAN MONOCLONAL REGN5458 .GAMMA.4-CHAIN) DISULFIDE WITH HUMAN MONOCLONAL REGN5458 .KAPPA.-CHAIN
LINVOSELTAMAB [USAN]
LYNOZYFIC
Linvoseltamab [WHO-DD]
Linvoseltamab-GCPT
REGN-5458
REGN5458
linvoseltamab [INN]

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.

LINVOSELTAMAB

Synonyms and Mappings

Resources